 Karyopharm Therapeutics Inc NASDAQ: KPTI announced updated data from Phase 12 trial of eltanexor ATG-016 for patients with hypomethylating agent HMA refractory myelodysplastic syndrome MDS. Data were presented at the 2021 American Society of Clinical Oncology Annual Meeting. 